Highland Capital Management LLC Purchases New Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Highland Capital Management LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,466 shares of the medical equipment provider’s stock, valued at approximately $1,383,000.

Several other large investors have also modified their holdings of the stock. Provence Wealth Management Group bought a new stake in shares of Intuitive Surgical during the fourth quarter valued at approximately $276,000. Portside Wealth Group LLC raised its holdings in shares of Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Intuitive Surgical by 5.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after buying an additional 9,869 shares during the last quarter. Finally, HCR Wealth Advisors raised its holdings in shares of Intuitive Surgical by 26.3% during the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock valued at $352,000 after buying an additional 217 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the transaction, the senior vice president now directly owns 883 shares in the company, valued at approximately $343,628.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total transaction of $589,484.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The disclosure for this sale can be found here. Insiders sold a total of 17,956 shares of company stock worth $6,927,011 in the last three months. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Up 0.1 %

Shares of NASDAQ:ISRG traded up $0.66 during midday trading on Friday, hitting $444.16. The stock had a trading volume of 1,151,601 shares, compared to its average volume of 1,360,739. The company’s 50-day moving average price is $417.08 and its 200-day moving average price is $390.78. The company has a market capitalization of $157.54 billion, a P/E ratio of 80.17, a price-to-earnings-growth ratio of 5.74 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $449.00.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.00 EPS. Research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ISRG shares. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. BTIG Research upped their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a report on Friday, April 19th. Robert W. Baird cut their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, Evercore ISI upped their price objective on shares of Intuitive Surgical from $385.00 to $425.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $410.32.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.